New York: US-based Pfizer and German biotech firm BioNTech have announced the start of a late stage clinical trial of a Covid-19 vaccine jointly developed by the two companies. The Phase 2/3 study will involve up to 30,000 participants between 18 and 85 years of age, the two companies said on Monday. Pfizer and BioNTech last week announced that the US government had agreed to pay $1.95 billion for 100 million doses of a potential Covid-19 vaccine jointly developed by them.
Monday marked the beginning of another late stage Covid-19 vaccine trial as pharmaceutical company Moderna announced the start of a phase-3 clinical trial to evaluate an investigational vaccine known as mRNA-1273.
This trial will also include 30,000 participants.